Status:
COMPLETED
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
Lead Sponsor:
Kyowa Kirin Co., Ltd.
Conditions:
Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Pha...
Eligibility Criteria
Inclusion
- Patients who did not respond or are refractory to available therapy or for whom no standard effective systemic therapy exists.
- Karnofsky performance status (KPS) ≥ 70%, or Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Patients with adequate organ function
Exclusion
- Anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of ARQ 197
- Known symptomatic brain metastases
- Pregnant or breastfeeding
- Uncontrolled intercurrent illness
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00609921
Start Date
January 1 2008
Last Update
September 7 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.